Clinical Trials
31 trialsNCT07213804 2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT07174336 2026-05-22
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT07218380 2026-05-22
FORAGER-2
Eli Lilly and Company
Phase 3 Recruiting
NCT07044336 2026-05-20
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
Phase 3 Recruiting
NCT07222566 2026-05-20
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
Phase 3 Recruiting
NCT06119581 2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3 Recruiting
NCT06757634 2026-05-18
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
Phase 3 Recruiting
NCT07562152 2026-05-15
MAPKeeper 301
Immuneering Corporation
Phase 3 Recruiting
NCT07205822 2026-05-12
TB06
AstraZeneca
Phase 3 Recruiting
NCT06500455 2026-05-04
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
Phase 3 Recruiting
NCT06103864 2026-04-30
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
AstraZeneca
Phase 3 Recruiting
NCT06346197 2026-04-21
CIME
Centre Leon Berard
Phase 3 Recruiting
NCT07222800 2026-04-21
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Phase 3 Recruiting
NCT06195709 2026-04-17
ECLECTIC
Institut Curie
Phase 3 Recruiting
NCT06064877 2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06072612 2026-04-07
BRIA-ABC
BriaCell Therapeutics Corporation
Phase 3 Recruiting
NCT06391242 2026-03-27
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT07281833 2026-02-27
CAPIcorn
West German Study Group
Phase 3 Recruiting
NCT06127407 2026-02-06
CHONQUER
Servier
Phase 3 Recruiting
NCT07221734 2026-01-21
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
mAbxience Research S.L.
Phase 3 Recruiting
NCT05717166 2025-12-31
SABR-SYNC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Recruiting
NCT06216301 2025-12-17
LUNAR-2
NovoCure Ltd.
Phase 3 Recruiting
NCT06174987 2025-10-15
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Daiichi Sankyo
Phase 3 Recruiting
NCT06173401 2025-07-16
Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases
Stanford University
Phase 3 Recruiting
NCT02885753 2025-07-09
OSCAR
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT05552001 2025-06-11
ISIdE
UNICANCER
Phase 3 Recruiting
NCT06897644 2025-05-25
PANThEON
Gruppo Oncologico del Nord-Ovest
Phase 3 Recruiting
NCT04747054 2024-10-26
PembroMetaRT
UNICANCER
Phase 3 Recruiting
NCT06275958 2024-10-16
DOSAGE
Leiden University Medical Center
Phase 3 Recruiting
NCT05352178 2024-07-03
SPARKLE
Universitaire Ziekenhuizen KU Leuven
Phase 3 Recruiting
NCT05854849 2023-05-11
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Sun Yat-sen University
Phase 3 Recruiting